COMP <GO>
VCYT vs MRK // EV/EBITDA & P/E VALUATION
Veracyte Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: VCYT 5
— MRK 9
▲ EV/EBITDA & P/E VALUATION LEADER: MRK
LAST: $49.00 (-2.02%) • MKT CAP: $4.02B
valuation
58.7x
LAST: $148.36 (-0.78%) • MKT CAP: $368.89B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VCYT VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VCYT | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 70.10% | 74.80% | -4.70 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.60% | 20.70% | -16.10 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 58.7x | 15.3x | +43.40 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 3.02% | 3.42% | -0.40 | MRK | /fcf-yield <GO> |
| Operating Margin | 11.20% | 34.30% | -23.10 | MRK | /operating-margins <GO> |
| Net Profit Margin | 12.80% | 28.10% | -15.30 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 16.00% | 1.30% | +14.70 | VCYT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.19 | +20.81 | VCYT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | VCYT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.7 | 56.3 | +1.40 | VCYT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.92 | +0.16 | VCYT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 53.1x | 18.4x | +34.70 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.02B | $368.89B | -$364.87B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VCYT REV | MRK REV | VCYT GROSS % | MRK GROSS % | VCYT FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $517.1M | $65.01B | 70.1% | 74.8% | $126.6M | $12.36B |
| FY 2024 | $445.8M | $64.17B | 66.9% | 76.3% | $63.8M | $18.10B |
| FY 2023 | $361.1M | $60.12B | — | — | $28.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VCYT // BETA 1.08
MRK // BETA 0.92